Phase II Study of STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2014
At a glance
- Drugs Ganetespib (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.
- 20 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Mar 2013 Planned end date changed from 1 Dec 2017 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History